Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: The central role of the patient risk profile

BJU International, Supplement

Volumn 95, Issue 4, 2005, Pages 1-5

  Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

1 adrenoceptor antagonists; 5 reductase inhibitors; BPH; Disease progression; Efficacy; LUTS; Tolerability

Indexed keywords

DISEASE COURSE; HIGH RISK PATIENT; HUMAN; MALE; MICTURITION DISORDER; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL FUNCTION; URINARY FREQUENCY; URINARY TRACT DISEASE; URINE INCONTINENCE;

ADRENERGIC ALPHA-ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS; MALE; PROSTATIC HYPERPLASIA; RISK ASSESSMENT; RISK FACTORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE 5-ALPHA-REDUCTASE; URINATION DISORDERS;

EID: 18944369819     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05484.x     Document Type: Review

References (30)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
2. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9
3. Abrams P, Cardozo L, Fall M et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003; 61: 37-49
4. Welch G, Kawachi I, Barry MJ, Giovannucci E, Colditz GA, Willett WC. Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the Health Professionals Follow-up Study. Urology 1998; 51: 422-7
5. Peters TJ, Donovan JL, Kay HE et al. The International Continence Society 'Benign Prostatic Hyperplasia' Study: the bothersomeness of urinary symptoms. J Urol 1997; 157: 885-9
6. DuBeau CE, Yalla SV, Resnick NM. Implications of the most bothersome prostatism symptoms for clinical care and outcomes research. J Am Geriatr Soc 1995; 43: 985-92
7. Lee AJ, Garraway WM, Simpson RJ, Fisher W, King D. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 1998; 34: 325-32
8. Dobrovits M, Chaudry A, Anagnostou T et al. A longitudinal prospective study of men with mild symptoms of BOO treated with watchful waiting over 4 years. Eur Urol 2003; (Suppl 2): 26 (Abstract 96)
9. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progressioin of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98
10. Artibani W. Integrating the patient risk profile in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol 2004; 3 (Suppl): 1-6
11. Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 2003; 62: 24-33
12. Trachtenberg J. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression. BJU Int 2005; 95 (Suppl 4): 6-11
13. Logie JW, Clifford GM, Farmer RD, Meesen BP. Lower urinary tract symptoms suggestive of benign prostatic obstruction - Triumph: the role of general practice databases. Eur Urol 2001; 39 (Suppl. 3): 42-7
14. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002; 167: 1734-9
15. Speakman MJ, Berges R, Desgrandchamps F et al. Integrating risk profiles in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia. A systematic analysis of expert opinion. Eur Urol Suppl 2004; 3: 61 (Abstract 232)
16. Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int 2005; 95 (Suppl 4): 12-18
17. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-49
18. Höfner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335-41
19. Tubaro A, Polito M, Giambroni L, Famulari C, Gange E, Ostardo E. Sexual function in patients with LUTS suggestive of BPH. Eur Urol 2001; 40 (Suppl. 1): 19-22
20. Barendrecht MM, Koopmans RP, de La Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 2005; 95 (Suppl 4): 19-28
21. Coffey DS. Controversies in the management of lower urinary tract symptoms: an overview. Br J Urol 1998; 81 (Suppl. 1): 1-5
22. Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schafers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 1998; 160: 784-91
23. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997; 19: 730-42
24. Kloner RA, Jackson G, Emmick JT et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172: 1935-40
25. Kloner RA. Novel phoshodiesterase type 5 inhibitors: assessing hemodynamic effectsand safety parameters. Clin Cardiol 2004; 27 (Suppl. 1): 120-5
26. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004; 64: 998-1004
27. Chapple CR. BHP Disease Management. Introduction and concluding remarks. Eur Urol 1999; 36 (Suppl. 3): 1-6
28. 1-adrenaceptor antagonists. BJU Int 2005; 95 (Suppl 4): 29-36
29. Djavan B, Chappie C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081-8
30. CDER New and Generic Drug Approvals: 1998-2004. URL http://www.fda.gov/ cder/approval/index.htm [accessed 24 February 2005]